Objective: To validate a complex association between schizophrenia and obsessive-compulsive disorder (OCD).
Key Words: comorbidity, obsessive-compulsive spectrum, schizophrenia, obsessive-compulsive disorder I dentification of etiopathogenetic mechanisms of schizophrenia is hampered by a substantial phenotypic heterogeneity of the disorder. The concept of a schizo-obsessive disorder was suggested to delineate a relatively homogeneous subgroup of patients characterized by the presence of obsessive-compulsive symptoms or of OCD in addition to positive, negative, and disorganized symptoms of schizophrenia (1) (2) (3) .
Although the identification of obsessive-compulsive symptoms in schizophrenia is challenging, data indicate that obsessions and compulsions can be identified as a separate dimension in patients with schizophrenia. Most recent reports point toward a substantial rate of OCD in schizophrenia (about 10% to 25%) that is revealed in both epidemiologic and clinical samples (4) . OCD has also been detected across the lifespan in adolescent, adult, and elderly schizophrenia patients (5, 6) . Obsessive-compulsive symptoms in schizophrenia do not seem to be sequelae to chronic illness or neuroleptic treatment since a comparable rate of OCD (14%) has been noted in first-episode, predominantly drug-naive, schizophrenia patients (7) . The validity of the association between schizophrenia and obsessive-compulsive symptoms or OCD is also supported by the outcome differences in schizophrenia patients with and without OCD: schizoobsessive individuals have poorer outcomes, more severe impairment of social behaviour, and lower levels of functioning (8, 9) .
OCD is a highly comorbid condition, of which MDD and anxiety disorders are the most frequently diagnosed comorbidities (10, 11) . OCD has also been strongly associated with somatoform disorders (for example, BDD and hypochondriasis), chronic tic disorders, and eating disorders (12, 13) . It has been suggested that some of these comorbid conditions (BDD and tic disorders) may share common etiologic pathways with OCD, while others (MDD) may represent secondary syndromes (10, 12) . Indeed, considerable overlap has been found in the clinical presentation, familial inheritance, basal ganglia dysfunction, and pharmacotherapy of BDD, tic disorders, and OCD, which supports the existence of a putative OCD spectrum (13) . If obsessive-compulsive symptoms represent a separate psychopathological dimension of schizophrenia, it is plausible that, similar to "pure" OCD, there is a preferential aggregation of OCD spectrum disorders in schizo-obsessive patients but not in their non-OCD schizophrenia counterparts. The results of our recent preliminary investigation support this hypothesis and show that OCD spectrum disorders, primarily BDD and chronic tic disorders, aggregate in schizo-obsessive but not in non-OCD schizophrenia patients (14) .
Our primary objective was to substantiate the findings of preferential aggregation of OCD spectrum disorders in schizo-obsessive patients in what is to date the largest well-defined subset of 100 patients who met DSM-IV criteria for both schizophrenia and OCD, compared with a non-OCD schizophrenia group. Our secondary goal was to compare the rate of other comorbid Axis I psychiatric disorders (MDD, anxiety, and substance use disorders) between the 2 schizophrenia groups. We also sought to compare the rate and pattern of aggregation of comorbid Axis I psychiatric disorders between schizo-obsessive and pure OCD groups of patients.
Method

Subjects
The study was conducted at Tirat Carmel Mental Health Center (Tirat Carmel, Israel), a psychiatric facility that serves a catchment area for a population of about 300 000. The study group included patients hospitalized owing to acute exacerbation of psychosis who met DSM-IV criteria for both schizophrenic disorder and OCD and who were admitted during the years 1996 to 2003. Of the 113 consecutively admitted schizophrenia patients with OCD who were approached, 100 individuals agreed to participate in the study. Patients with affective and organic mental disorders or drug-or alcohol-induced psychoses, as well as those with antipsychotic-induced OCD, were not included. The major comparison group included 100 (of 109 approached) schizophrenia patients without OCD who were matched for age (within 3 years) and number of hospitalizations to the schizo-obsessive group and who were admitted to the same treatment facility during the same time period. There were no statistical sociodemographic or clinical differences between (14) . There were no significant differences in demographic or clinical characteristics between the previously reported and the present samples (data not shown).
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The second comparison group included 35 (of 37 approached) nonschizophrenia OCD patients who were treated in either the same inpatient facility (n = 6) or in the outpatient clinic of Tirat Carmel Hospital (n = 29). We excluded 2 patients who had a history of head trauma.
The study was approved by the Institutional Review Board of Tirat Carmel Mental Health Center. All participants gave written informed consent after receiving a full explanation of the study protocol.
Clinical Assessments
We used the SCID-IP (15) to diagnose schizophrenic disorders and OCD as well as the additional comorbid psychiatric disorders. All participants underwent a direct clinical interview. The researchers also collected information from all available sources, including medical records, interviews with family members, and treating clinicians. Patients from the 2 schizophrenia groups were interviewed after resolution of acute psychosis, when they were cooperative enough to undergo a structured clinical interview.
We evaluated the severity and content of current and lifetime obsessive-compulsive symptoms with the Y-BOCS and its incorporated symptom checklist (16) . To be included in the schizo-obsessive group, patients had to have typical obsessive-compulsive symptoms, that is, time-consuming (³ 1 hour), distressful obsessions and (or) compulsions that significantly interfered with the patient's functioning, as revealed by the symptom checklist. Since the present study focused on clinically significant obsessive-compulsive symptoms in schizophrenia, we operationally defined the duration of obsessive-compulsive symptoms as no less than 6 months and did not include those patients who had transient obsessive-compulsive symptoms. If obsessive-compulsive symptoms were related to the content of delusions or formal thought disorders, we required the presence of additional typical obsessive-compulsive symptoms (from the Y-BOCS checklist). We excluded patients with subthreshold OCD as assessed by the SCID-IP and the Y-BOCS, as well as patients who exhibited obsessive-compulsive symptoms exclusively restricted to positive schizophrenia symptoms (for example, compulsive hand washing owing to command hallucinations or obsessive preoccupation with "feelings of discontinuation of normal flow of thoughts").
We assessed the severity of schizophrenic symptoms with the SAPS (17), the SANS (18), and the CGI for psychosis (19) .
We defined the psychiatric comorbid disorders, according to evaluation with the SCID, as the presence of additional lifetime or concurrent DSM-IV Axis I psychiatric diagnoses. For this study, we screened participants for MDD, substance use disorders, anxiety disorders (panic disorder with and without agoraphobia, social phobia, and simple phobia), BDD, hypochondriasis, and eating disorders (anorexia nervosa and bulimia nervosa). We diagnosed chronic tic disorders and Tourette syndrome with additional modules based on DSM-IV criteria. For the diagnosis of BDD we required the presence of typical preoccupation with an imagined or exaggerated bodily defect associated with significant distress and (or) functional impairment unrelated to schizophrenia symptoms (20) . If preoccupation with bodily defect was exclusively restricted to the patients' delusional or hallucinatory experience, the cases were not included. We applied similar requirements to the diagnosis of hypochondriasis. The false belief regarding a serious illness despite the absence of pathological findings on medical examinations had no delusional intensity and had to cause distress or functional impairment. We did not consider subthreshold diagnoses. We did use lifetime diagnoses in the analysis. We defined OCD spectrum disorders as the sum of the rates of occurrence of BDD, hypochondriasis, eating disorders (anorexia nervosa and bulimia nervosa), and tic disorders (chronic tic disorder or Tourette syndrome).
We estimated age at onset of schizophrenia (emergence of first psychotic symptoms) and age at onset of OCD (first occurrence of clinically significant obsessions and [or] compulsions), using all available information from patients, medical records, and caregivers. We defined the duration of illness as the difference between age at interview and age at onset of illness.
All clinical interviews were conducted by 2 trained residents in psychiatry and 1 psychologist under the supervision of 2 senior psychiatrists who have extensive experience in the clinical evaluation of patients with schizophrenia, schizo-obsessive disorder, and OCD spectrum disorders. The interviewers were not blind to the patients' group assignments; however, the 2 supervisors who confirmed the diagnoses of comorbid psychiatric disorders were. Interrater reliability among the raters was high for both primary and comorbid diagnoses (ê = 0.69 to 0.94).
Statistical Analysis
All statistical analyses were performed with SPSS, version 12 (SPSS Inc, Chicago, IL). We compared between-group differences in demographic and clinical characteristics using ANOVA and the chi-square test, as appropriate. We considered a 2-tailed P value of less than 0.05 significant.
We used stepwise logistic regression to analyze between-group differences in Axis I comorbid disorders. According to the hierarchy of the study objectives, we first evaluated the difference between the 2 schizophrenia groups (with and without OCD) in the individual and combined OCD spectrum disorders. This was followed by the analysis of the between-group differences in the remaining comorbid disorders (MDD, anxiety, and substance use disorders). We then applied a similar procedure to the analysis of the differences between the schizo-obsessive and the OCD groups in the OCD spectrum and the remaining comorbid disorders. Variables were entered into the model sequentially. At each step, we entered the variable with the minimum P value into the model, provided that the value was less than 0.05. Comorbid psychiatric diagnoses (individual and pooled OCD spectrum disorders, MDD, combined anxiety disorders, and substance use disorders) were the dependent variables of a logistic model dichotomized as present or absent. The group was the main independent variable. The other explanatory variables were those that differed significantly between the 2 groups. Thus, in the comparison between the schizophrenia groups with and without OCD, the potential covariates were the age of onset and the duration of schizophrenia. In the comparison between the schizo-obsessive and the OCD group, the potential covariates were sex, years of education, employment, and marital status. When only the grouping variable enters the model with a significant coefficient, the â-coefficient equals the log OR, and the exponent (â) equals the OR. When additional variables enter the model, the exponent (â) for the grouping variable can be considered an adjusted OR. For the models in which the grouping variables enter the logistic model, we present the respective P values and OR (or adjusted ORs) with the appropriate confidence intervals. Whenever one of the comorbid disorders has a zero frequency, we present only the appropriate P value.
Results
Comparison Between the Schizo-Obsessive and the Non-OCD Schizophrenia Group
Demographic and Clinical Characteristics. About 75% of patients in the 2 schizophrenia groups were men, had a similar mean age at interview, had completed a similar number of years of education,and had a similar number of hospitalizations ( Table 1) . The 2 schizophrenia groups were also remarkably similar in the proportion of patients who were unmarried and unemployed. The patients in the schizo-obsessive group had a significantly earlier age of onset of schizophrenia and a longer duration of illness, compared with the non-OCD schizophrenia group (F 1,198 = 8.79; P = 0.003 and F 1,198 = 11.08; P = 0.001, respectively). We did not find any between-group differences in the severity of schizophrenia symptoms as they were assessed by the SAPS, the SANS, and the CGI. As anticipated, patients in the schizo-obsessive group scored significantly higher than their non-OCD counterparts on the Y-BOCS (Table 1) .
More than one-half of the patients in each schizophrenia group met DSM-IV criteria for at least one nonschizophrenia Axis I comorbid disorder (Table 2 ). We found 2 or more comorbid disorders in 23 and 16 patients, respectively.
Comorbid OCD Spectrum Disorders. Compared with the schizophrenia group, the schizo-obsessive group had a significantly higher rate of BDD and tic disorders (Tables 2 and 3 ). There was also a higher rate of comorbid eating disorders in the schizo-obsessive group; however, the difference was no longer significant after we adjusted for the age of illness onset.
We did not find a between-group difference in the rate of hypochondriasis. Overall, combining OCD spectrum disorders yielded a robust between-group difference in several patients with at least one OCD spectrum disorder (P = 0.018 after Bonferroni correction). We found 2 OCD spectrum disorders in 8 of the 100 patients in the schizo-obsessive group and did not find any in the schizophrenia group (÷² = 8.33; P = 0.0039).
Comorbid Affective, Anxiety, and Substance Use Disorders. MDD was the most frequent comorbid disorder in both schizophrenia groups, followed by substance use, and combined anxiety disorders (Table 2) . We found no between-group differences in the frequency of either MDD or combined anxiety disorders (Table 3) . Although the schizo-obsessive group had a lower rate of substance use disorders, the between-group difference was no longer significant after adjusting for the duration of illness (Table 3) .
Interestingly, within the schizo-obsessive group the patients with and without additional comorbid disorders did not differ significantly on any of the demographic or clinical characteristics (data not shown).
Comparison Between the Schizo-Obsessive Group and the OCD Group
Compared with the schizo-obsessive group, the OCD group had a substantially higher percentage of women (÷² = 9.33, P = 0.0022), married and employed individuals (÷² = 21.27, P < 0.001; and ÷² = 4.68, P = 0.031, respectively), and fewer hospitalizations (t = 8.79, P < 0.000) ( Table 1 ). There were no between-group differences in age of onset or duration of OCD. Patients in the 2 groups had similar severity of obsessive-compulsive symptoms, as indicated by the Y-BOCS scores (Table 1) .
Overall, 80% (n = 28) of the 35 OCD patients had at least one Axis I comorbid psychiatric disorder, compared with 57% (n = 57) of the 100 patients in the schizo-obsessive group.
Comorbid OCD Spectrum Disorders. We did not find any significant between-group difference in the proportion of patients with at least one OCD spectrum disorder. Regarding individual OCD spectrum disorders, the groups did not differ significantly in the rate of BDD, eating disorders, or hypochondriasis; however, the schizo-obsessive group had a lower rate of tic disorders (Tables 2 and 3) .
Comorbid Affective, Anxiety, and Substance Use Disorders. In the OCD group, MDD and anxiety disorders were the most frequent comorbid disorders (65.7% and 31.5%, respectively), while the rate of substance use (2.9%) was the lowest. Compared with the OCD group, the schizo-obsessive group had significantly lower rates of MDD and combined anxiety disorders. We found no difference in the rate of substance use disorders between the groups (Table 3) .
Discussion
This study directly compared the rates of Axis I psychiatric disorders in schizophrenia patients with and without OCD. Consistent with our hypothesis, we found a robust differentiation between the 2 schizophrenia groups with respect to the combined OCD spectrum disorders evaluated in the study. This difference was primarily explained by the substantially higher rates of BDD and tic disorders in the schizo-obsessive group, compared with the non-OCD schizophrenia group. Moreover, only the schizo-obsessive group included patients who had 2 comorbid OCD spectrum disorders. In contrast, we did not find any significant between-group differences in the rates of MDD, anxiety disorders, and substance use disorders. These findings suggest that there is a specific elevation in the rate of OCD spectrum disorders in the schizo-obsessive group rather than a generalized elevation of psychopathology. Finally, the comparable rate of OCD spectrum disorders found in the schizo-obsessive and OCD groups, both substantially higher than in the non-OCD schizophrenia group, lends additional support to the hypothesis of preferential aggregation of OCD spectrum disorders in the schizo-obsessive subgroup. Notably, more than one-half of the patients in each schizophrenia group had at least one comorbid Axis I disorder; about one-third had MDD and about 15% had an anxiety disorder. These findings are in accordance with the prevalence of comorbid affective and anxiety disorders other than OCD found in schizophrenia patients with similar clinical characteristics (21, 22) . This provides additional support for the validity of our study. The odds of having substance use disorders in the schizo-obsessive group were one-half those found in the non-OCD schizophrenia group and were comparable to the OCD group. These findings merit explicit evaluation in larger samples. If confirmed, the presence of OCD in schizophrenia may serve as a protective factor against substance use, similar to pure OCD (23) .
From a clinical perspective, the findings of an aggregation of OCD spectrum disorders in schizo-obsessive patients justify a systematic search for and assessment of these comorbidities, particularly in a schizo-obsessive subset. Conversely, since the presence of OCD spectrum disorders increases the odds of OCD in schizophrenia patients, targeting these additional syndromes may improve identification of an obsessive-compulsive component in schizophrenia.
Within the OCD spectrum disorders evaluated in this study, a significant difference between the 2 schizophrenia groups was revealed for BDD and chronic tic disorders. We detected BDD only in the schizo-obsessive group and not in the non-OCD schizophrenia group. The proportions of patients with BDD in the schizo-obsessive group and in the OCD group were also remarkably similar. These findings indicate that OCD, either in its pure form or in association with schizophrenia, is associated with increased odds for cooccurrence with BDD, which further supports the categorization of both disorders as part of the OCD spectrum. Since the sample size is 100, the number of patients equals the percentage.
In this study, the odds of having chronic motor tic disorders in the schizo-obsessive group were 4 times higher than those of the schizophrenia group. It is of note that we did not detect any cases of Tourette syndrome in the schizo-obsessive group. It has been suggested that Tourette syndrome and chronic tic disorders are part of the same disease entity, with Tourette syndrome being a more severe and complex form of tic disorder (24) . If replicated, our findings suggest that an obsessive-compulsive component in schizophrenia represents a subgroup of the disorder that is unrelated to Tourette syndrome (25) . This may then have implications for further research into the pathogenetic mechanisms of the schizo-obsessive association.
The present study has several limitations. The identification of comorbid disorders may be hampered by the limited awareness of illness in schizophrenia patients. In our study, all patients were interviewed after resolution of active psychosis, and we used multiple sources of information including reports from first degree relatives. There are no data indicating that schizo-obsessive patients have poorer awareness of illness. It is therefore likely that this phenomenon was equally distributed between the 2 schizophrenia groups. Further, the SCID does not assess all possible OCD spectrum disorders, such as trichotillomania, which seemed to be more prevalent in schizo-obsessive patients. Thus the present data likely represent an underestimate of true OCD spectrum comorbidity. In addition, exclusion of subsyndromal forms of the disorders may also contribute to underestimated comorbidity rates. The cross-sectional design of the study precludes evaluation of temporal interrelations between comorbid disorders. Finally, because of the hierarchical hypothesis testing, we did not control for multiple comparisons; however, the difference between the 2 schizophrenia groups in pooled OCD spectrum disorders (30.0%, compared with 8%; P = 0.001) remains robust after Bonferroni correction (0.001 × 18 = 0.018).
Overall, the presence of OCD in schizophrenia patients appears to have a considerable effect on clinical outcomes of schizophrenia, including preferential aggregation of OCD spectrum disorders. The severity of schizophrenia symptoms experienced by our schizophrenia patients with and without OCD did not differ significantly, which is similar to some reports (1,3) but not to others (5,7). Earlier age of onset in the schizo-obsessive group merits further investigation and is noteworthy since it may indicate the accentuated neurodevelopmental origin of this schizophrenia subgroup. Finally, therapeutic interventions to address potentially treatable OCD spectrum disorders in schizophrenia patients, both pharmacologic and psychotherapeutic, are currently being developed (26) (27) (28) . Adjusted for the duration of schizophrenia c Zero frequency in the non-OCD schizophrenia group CI = confidence interval; ns = not significant unresolved. To clarify this issue, future research should focus on the evaluation of a temporal interrelation between schizophrenia and the OCD component within a schizo-obsessive subgroup during the course of illness. Familial coaggregation and cotransmission of schizophrenia spectrum and OCD-related disorders may also lend support to the existence of a schizo-obsessive entity (29) . Identification of specific biological markers and genetic underpinnings will contribute to the validation of this complex schizo-obsessive association and its delineation from pure forms of the disorders.
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Résumé : L'agrégation préférentielle des troubles du spectre obsessionnel-compulsif chez les patients souffrant de schizophrénie et de TOC Objectif : Valider une association complexe entre la schizophrénie et le trouble obsessionnel-compulsif (TOC).
Méthode : Nous avons utilisé l'entrevue clinique structurée pour les troubles de l'axe I du DSM-IV afin de comparer le taux des troubles du spectre du TOC et des troubles de l'axe I additionnels chez 100 patients qui satisfaisaient aux critères de la schizophrénie et du TOC, de la schizophrénie sans TOC (n = 100), et du TOC (n = 35).
Résultats : Il y avait une forte différence intergroupes du nombre de patients souffrant de un ou plus trouble du spectre du TOC (schizo-obsessionnel n = 30, comparé à la schizophrénie n = 8; P = 0,001), c'est-à-dire des taux supérieurs de peur d'une dysmorphie corporelle (8 % comparé à 0 %) et de troubles tics (16 % comparé à 4 %). Aucune différence n'a été révélée dans les troubles affectifs, anxieux et liés à une substance. Nous avons constaté des taux comparables des troubles du spectre du TOC dans le groupe schizo-obsessionnel et dans le groupe du TOC (30 % et 42,8 %, respectivement; P = 0,32).
Conclusion :
L'agrégation préférentielle des troubles du spectre du TOC dans le groupe schizo-obsessionnel soutient cette association clinique unique. Il faut plus de recherche pour déterminer si une interface schizo-obsessionnelle représente une comorbidité ou un sous-type spécifique de la schizophrénie.
